These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3046888)

  • 1. Lovastatin for hypercholesterolemia.
    Zeller FP; Uvodich KC
    Drug Intell Clin Pharm; 1988; 22(7-8):542-5. PubMed ID: 3046888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lovastatin: a new cholesterol-lowering agent.
    McKenney JM
    Clin Pharm; 1988 Jan; 7(1):21-36. PubMed ID: 3278832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lovastatin: a new cholesterol-lowering agent.
    Krukemyer JJ; Talbert RL
    Pharmacotherapy; 1987; 7(6):198-210. PubMed ID: 3328165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
    Weber C; Erl W; Weber KS; Weber PC
    J Am Coll Cardiol; 1997 Nov; 30(5):1212-7. PubMed ID: 9350917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
    Davidson M; McKenney J; Stein E; Schrott H; Bakker-Arkema R; Fayyad R; Black D
    Am J Cardiol; 1997 Jun; 79(11):1475-81. PubMed ID: 9185636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of lovastatin in primary hypercholesterolemia].
    Nakandakare ER; Garcia RC; Carré JM; Zerbinatti CV; Oliveira HC; Quintão EC
    Arq Bras Cardiol; 1989 May; 52(5):291-5. PubMed ID: 2690785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
    Illingworth DR; Bacon S
    Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of clinical trials comparing HMG-CoA reductase inhibitors.
    Illingworth DR; Tobert JA
    Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol.
    Frishman WH; Rapier RC
    Med Clin North Am; 1989 Mar; 73(2):437-48. PubMed ID: 2645482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lovastatin versus bezafibrate: efficacy, tolerability, and effect on urinary mevalonate.
    Beil FU; Schrameyer-Wernecke A; Beisiegel U; Greten H; Karkas JD; Liou R; Alberts AW; Eckardt HG; Till AE
    Cardiology; 1990; 77 Suppl 4():22-32. PubMed ID: 2073669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of lovastatin on serum lipids in patients with nonfamilial primary hypercholesterolemia.
    Itskovitz HD; Flamenbaum W; De Gaetano C; Pritchard KA; Stemerman MB
    Clin Ther; 1989; 11(6):862-72. PubMed ID: 2611825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment (2 years) with the HMG CoA reductase inhibitors lovastatin or pravastatin in combination with cholestyramine in patients with severe primary hypercholesterolemia.
    Jacob BG; Richter WO; Schwandt P
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):396-400. PubMed ID: 7504129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II.
    JAMA; 1986 Nov; 256(20):2829-34. PubMed ID: 3534333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.
    Bradford RH; Shear CL; Chremos AN; Dujovne C; Downton M; Franklin FA; Gould AL; Hesney M; Higgins J; Hurley DP
    Arch Intern Med; 1991 Jan; 151(1):43-9. PubMed ID: 1985608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meeting national cholesterol education goals in clinical practice--a comparison of lovastatin and fluvastatin in primary prevention.
    Nash DT
    Am J Cardiol; 1996 Sep; 78(6A):26-31. PubMed ID: 8875972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and long-term adverse effect pattern of lovastatin.
    Tobert JA
    Am J Cardiol; 1988 Nov; 62(15):28J-34J. PubMed ID: 3055921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
    Aviram M; Hussein O; Rosenblat M; Schlezinger S; Hayek T; Keidar S
    J Cardiovasc Pharmacol; 1998 Jan; 31(1):39-45. PubMed ID: 9456275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.